CAI
Clinical Asset Index
by VOS Supply Group
Drugs · acquisition-cost intelligence

Morphine Sulfate Extended Release

morphine sulfate· ingredient morphineNatural opium alkaloids· MORPHINE SULFATE 100 mg/1; MORPHINE SULFATE 15 mg/1; MORPHINE SULFATE 200 mg/1; MORPHINE SULFATE 30 mg/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$0.64606
NADAC — pharmacy acquisition cost, not a retail/cash price

Acquisition-cost history

Weekly NADAC per EA — the trend nobody else shows. 7 weeks.

2025-07-012026-05-20

Same-ingredient options by acquisition cost

Other morphine products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.

ProductNADAC / EAvs this
morphine sulfate$0.31703−$0.32900
Morphine Sulfate$0.32100−$0.32510
Morphine Sulfate ER$0.36102−$0.28500
morphine sulfate$0.41377−$0.23230
Morphine Sulfate$2.32+$1.67
morphine sulfate$2.86+$2.22

Medicare Part D coverage · CY2026

On 327 plan formularies · typical tier 3
Prior auth 50% · Step therapy 0% · Quantity limit 88% of formularies

Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.